Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Dose-exploration, Open-label Phase II Study to Evaluate the Efficacy and Safety of EDP167 in Adult Patients With Homozygous Familial Hypercholesterolaemia

NCT07489209 is registered in ClinicalTrials.gov with Eddingpharm (Zhuhai) Co., Ltd. as lead sponsor.

NCT NCT07489209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07489209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Dose-exploration, Open-label Phase II Study to Evaluate the Efficacy and Safety of EDP167 in Adult Patients With Homozygous Familial Hypercholesterolaemia
Lead sponsor
Eddingpharm (Zhuhai) Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
February 6, 2026
Completion date
March 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

homozygous familial hypercholesterolemia (hofh)